lobbying_activities: 3009636

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
3009636	e09bcadb-8d8e-4e02-a06a-815b2f44dd7b	Q2	AMERICAN CLINICAL LABORATORY ASSN	1923	AMERICAN CLINICAL LABORATORY ASSN	2023	second_quarter	MED	Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, new test coding and pricing, definitive drug testing coding, coverage, and payment, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); FDA and CMS policies related to diagnostics and laboratory regulation; reauthorization of the Pandemics and All-Hazards Preparedness Act (PL. 109-417); price transparency for clinical laboratory services, FY 2024 budget and appropriations processes Saving Access to Laboratory Services Act H.R. 2377/S. 1000, VALID Act H.R. 2369; H.R. 3791, Improving Data in Public Health Act; H.R. 3248, Diagnostic Lab Testing Transparency Act;	Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office		633739	0	0	2023-07-18T11:26:24-04:00